News 30 avr 2024 Top Stories from Western Switzerland (April 2024) From biotech breakthroughs and the transformation of clinical trials to advancements in eco-friendly materials and renewable energy initiatives, ...
News 06 mai 2024 EY reports growth of 53 percent for investments in Switzerland Foreign investments in Europe fell by 4 percent in 2023. However, investments in Switzerland were up by 53 percent. These findings were reported ...
Actualités 30 avr 2024 Les Grands Titres de Suisse occidentale (Avril 2024) De percées biotechnologiques à la transformation des essais cliniques, en passant par des avancées dans le domaine des matériaux écologiques et d...
Aktuell 06 mai 2024 EY meldet Plus von 53 Prozent bei Investitionen in der Schweiz Ausländische Investitionen in Europa sind 2023 um 4 Prozent gesunken. Die Investitionen in der Schweiz sind dagegen um 53 Prozent gestiegen. Das ...
News 10 jan 2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
Actualités 10 jan 2024 L’essor remarquable de la chimie-pharma dans le canton du Valais Depuis des décennies, le canton du Valais a cultivé une réputation d’excellente dans les domaines de la chimie et de la pharmaceutique, fusionnan...
News 14 aoû 2023 Bern’s thriving ecosystem for life sciences innovation In the heart of Western Switzerland, the canton of Bern has emerged as a location of choice for companies in the life sciences sector.
News 29 sep 2023 Top Stories from Western Switzerland (July-September 2023) From spearheading eco-innovative solutions to pioneering breakthroughs in solar technology, cancer research, sustainable shipping, and the realms...
News 08 mar 2023 Oculis lists on Nasdaq with strong clinical-stage pipeline in ophthalmology Oculis Holding AG, a global biopharmaceutical company focused on saving sight and improving eye care, has announced its listing on the Nasdaq sto...
Actualités 14 aoû 2023 L’écosystème florissant de Berne pour l’innovation en sciences de la vie Au cœur de la Suisse occidentale, le canton de Berne s'est imposé comme une destination de choix pour les entreprises du secteur des sciences de ...
News 18 jan 2023 Calciscon enters Eurostars project to improve patient care worldwide Calciscon, together with Amsterdam University Medical Centers and ADMESY, have signed a collaborative agreement for the development of a laborato...
News 23 nov 2022 Geneva biopharma ObsEva sells its Ebopiprant license for up to USD 113 million Women's and reproductive health specialist ObsEva has announced the sale of its license for ebopiprant to California-based biotech company Xoma f...
Actualités 18 jan 2023 Calciscon participe à un projet Eurostars pour améliorer les soins aux patients Calciscon, ainsi que les centres médicaux universitaires d’Amsterdam et ADMESY, ont signé un accord de collaboration pour le développement d’un a...
News 01 fév 2022 Merck acquires Geneva-based biopharmaceutical company Chord Therapeutics Chord Therapeutics, a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, is being acquired by Merck.
News 27 oct 2021 ONWARD Medical goes public and raises CHF 93 million EPFL spin-off ONWARD Medical went public on Euronext Brussels with a secondary listing on Euronext Amsterdam, bringing the value of the company t...
News 19 oct 2021 Loop Medical raises USD 6.4 million to conquer US market Vaud-based healthcare start-up Loop Medical has completed a USD 6.4 million Series A financing round for its innovative blood collection device.
News 12 oct 2021 Neurotherapeutics pioneer MindMaze secures USD 125 million MindMaze, a global pioneer in the digital neurotherapeutics market, raised USD 125 million from AlbaCore Capital Group. This brings the Vaud-base...